|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effectiveness of probiotics in irritable bowel syndrome:Updated systematic review with meta-analysis显示文摘AIM:To investigate the efficacy of probiotics in irritable bowel syndrome(IBS) patients.METHODS:Pub Med,Cochrane library,Scopus,Google Scholar,and Clinicaltrial.gov databases were searched for literature published between September 2007 and December 2013.The applied Mesh terms were 'probiotics,' 'irritable bowel syndrome,' and 'irritable bowel syndrome treatment.' The collected data contained24 clinical trials,of which 15 were eligible for meta-analysis and nine were reviewed systematically.All studies were randomized placebo-controlled trials in patients with IBS that investigated the efficacy of probiotics in IBS improvement.The Jadad score was used to assess the methodological quality of trials.The quality scale ranges from 0 to 5 points,with a score ≤ 2 indicating a low quality report,and a score of ≥3 indicating a high quality report.Relative risk(RR),standardized effect size,and 95%CI were calculated using the Der Simonian-Laird method.The Cochran Q test was used to test heterogeneity with P < 0.05.Funnel plots were constructed and Egger's and BeggMazumdar tests were performed to assess publication bias.RESULTS:A total of 1793 patients were included in the meta-analysis.The RR of responders to therapies based on abdominal pain score in IBS patients for two included trials comparing probiotics to placebo was 1.96(95%CI:1.14-3.36;P = 0.01).RR of responders to therapies based on a global symptom score in IBS patients for two included trials comparing probiotics with placebo was 2.43(95%CI:1.13-5.21;P = 0.02).For adequate improvement of general symptoms in IBS patients,the RR of seven included trials(six studies) comparing probiotics with placebo was 2.14(95%CI:1.08-4.26;P = 0.03).Distension,bloating,and flatulence were evaluated using an IBS severity scoring system in three trials(two studies) to compare the effect of probiotic therapy in IBS patients with placebo,the standardized effect size of mean differences for probiotics therapy was-2.57(95%CI:-13.05--7.92).CONCLUSION:Probiotics reduce pain and symptom severity scores.The results demonstrate the beneficial effects of probiotics in IBS patients in comparison with placebo. | Tina Didari Shilan Mozaffari Shekoufeh Nikfar Mohammad Abdollahi | 2015 | World Journal of Gastroenterology2015，21，10： | 51 |
| 2 | Effi cacy of tricyclic antidepressants in irritable bowel syndrome:A meta-analysis显示文摘We aimed to evaluate the efficacy of tricyclic antidepressants(TCAs) as a therapeutic option for irritable bowel syndrome(IBS) through meta-analysis of randomized controlled trials.For the years 1966 until September 2008,PubMed,Scopus,Web of Science,and Cochrane Central Register of Controlled Trials were searched for double-blind,placebo-controlled trials investigating the effi cacy of TCAs in the management of IBS.Seven randomized,placebo-controlled clinical trials met our criteria and were included in the metaanalysis.TCAs used in the treatment arm of these trials included amitriptyline,imipramine,desipramine,doxepin and trimipramine.The pooled relative risk for clinical improvement with TCA therapy was 1.93(95% CI:1.44 to 2.6,P<0.0001).Effect size of TCAs versus placebo for mean change in abdominal pain score among the two studies was -44.15(95% CI:-53.27 to -35.04,P<0.0001).It is concluded that low dose TCAs exhibit clinically and statistically signifi cant control of IBS symptoms. | Roja Rahimi Shekoufeh Nikfar Ali Rezaie Mohammad Abdollahi | 2009 | World Journal of Gastroenterology2009，15，13： | 22 |
| 3 | A systematic review of effi cacy and tolerability of mebeverine in irritable bowel syndrome显示文摘We evaluated the eff icacy and tolerability of mebeverine, a musculotropic antispasmodic agent, in irritable bowel syndrome (IBS) and compared its usual dosages by meta-analysis. Medical databases and all relevant literature were searched from 1965 to June 2009 for any placebo-controlled clinical trials of mebeverine, using search terms such as mebeverine, clinical trials, and IBS. Eight randomized trials met our criteria, including six trials that compared mebeverine with placebo and two that compared mebeverine tablets with capsules. These eight trials included 555 patients randomized to receive either mebeverine or placebo with 352 (63%)women and 203 (37%) men in all subtypes of IBS. The pooled relative risk (RR) for clinical improvement of mebeverine was 1.13 (95% CI: 0.59-2.16, P = 0.7056) and 1.33 (95% CI: 0.92-1.93, P = 0.129) for relief of abdominal pain. The efficacy of mebeverine 200 mg compared to mebeverine 135 mg indicated RRs of 1.12 (95% CI: 0.96-1.3, P = 0.168) for clinical or global improvement and 1.08 (95% CI: 0.87-1.34, P = 0.463) for relief of abdominal pain. Thus, mebeverine is mostly well tolerated with no signif icant adverse effects; however, its eff icacy in global improvement of IBS is not statistically signif icant. | Mahnaz Darvish-Damavandi Shekoufeh Nikfar Mohammad Abdollahi | 2010 | World Journal of Gastroenterology2010，16，5： | 17 |
| 4 | Antioxidant therapy in the management of acute,chronic and post-ERCP pancreatitis:A systematic review显示文摘We systematically reviewed the clinical trials which recruited antioxidants in the therapy of pancreatitis and evaluated whether antioxidants improve the outcome of patients with pancreatitis.Electronic bibliographic databases were searched for any studies which investigated the use of antioxidants in the management of acute pancreatitis(AP)or chronic pancreatitis(CP)and in the prevention of post-endoscopic retrograde cholangio-pancreatography(post-ERCP)pancreatitis(PEP)up to February 2009.Twenty-two randomized,placebo-controlled,clinical trials met our criteria and were included in the review.Except for a cocktail of antioxidants which showed improvement in outcomes in three different clinical trials,the results of the administration of other antioxidants in both AP and CP clinical trials were incongruent and heterogeneous.Furthermore,antioxidant therapy including allopurinol and N-acetylcysteine failed to prevent the onset of PEP in almost all trials.In conclusion,the present data do not support a benefit of antioxidant therapy alone or in combination with conventional therapy in the management of AP,CP or PEP.Further double blind,randomized,placebo-controlled clinical trials with large sample size need to be conducted. | Seyed Sajad Mohseni Salehi Monfared Hamed Vahidi Amir Hossein Abdolghaffari Shekoufeh Nikfar Mohammad Abdollahi | 2009 | World Journal of Gastroenterology2009，15，36： | 10 |
| 5 | Antioxidant therapy in acute,chronic and post-endoscopic retrograde cholangiopancreatography pancreatitis:An updated systematic review and meta-analysis显示文摘AIM:To investigate the efficacy and adverse effects of antioxidant therapy in acute pancreatitis(AP),chronic pancreatitis(CP) and post-endoscopic retrograde cholangiopancreatography pancreatitis(PEP).METHODS:Pub Med,Scopus,Google Scholar,Cochrane library database,and Evidence-based medicine/clinical trials published before August 2014 were searched. Clinical and laboratory outcomes of randomized trials of antioxidant therapy in patients with AP,CP and PEP were included. The methodological quality of the trials was assessed by the Jadad score based on the description of randomization,blinding,and dropouts(withdrawals). The results of the studies were pooled and meta-analyzed to provide estimates of the efficacy of antioxidant therapy.RESULTS:Thirty four trials out of 1069 potentially relevant studies with data for 4898 patients wereeligible for inclusion. Antioxidant therapy significantly reduced the length of hospital stay in AP patients {mean difference-2.59 d(95%CI:-4.25-(-0.93)],P = 0.002}. Although,antioxidant therapy had no significant effect on serum C reactive protein(CRP) after 5-7 d in AP patients [mean difference-9.57(95%CI:-40.61-21.48,P = 0.55],it significantly reduced serum CRP after 10 d {mean difference-45.16 [95%CI:-89.99-(-0.33)],P = 0.048}. In addition,antioxidant therapy had no significant effect on CP-induced pain [mean difference-2.13(95%CI:-5.87-1.6),P = 0.26]. Antioxidant therapy had no significant effects on the incidence of all types of PEP [mean difference 1.05(95%CI:0.74-1.5),P = 0.78],severe PEP [mean difference 0.92(95%CI:0.43-1.97),P = 0.83],moderate PEP [mean difference 0.82(95%CI:0.54-1.23),P = 0.33],and mild PEP [mean difference 1.33(95%CI:0.99-1.78),P = 0.06]. Furthermore,while antioxidant therapy had no significant effect on serum amylase after less than 8 h sampling [mean difference-20.61(95%CI:-143.61-102.39),P = 0.74],it significantly reduced serum amylase close to 24-h sampling {mean difference-16.13 [95%CI:-22.98-(-9.28)],P < 0.0001}.CONCLUSION:While there is some evidence to support antioxidant therapy in AP,its effect on CP and PEP is still controversial. | Maziar Gooshe Amir Hossein Abdolghaffari Shekoufeh Nikfar Parvin Mahdaviani Mohammad Abdollahi | 2015 | World Journal of Gastroenterology2015，21，30： | 6 |
| 6 | Induction of clinical response and remission of inflammatory bowel disease by use of herbal medicines:A meta-analysis显示文摘AIM:To evaluate the efficacy and tolerability of herbal medicines in inflammatory bowel disease(IBD)by conducting a meta-analysis.METHODS:Electronic databases were searched for studies investigating efficacy and/or tolerability of herbal medicines in the management of different types of IBD.The search terms were:'herb'or'plant'or'herbal'and'inflammatory bowel disease'.Data were collected from 1966 to 2013(up to Feb).The'clinical response','clinical remission','endoscopic response','endoscopic remission','histological response','histological remission','relapse','any adverse events',and'seriousadverse events'were the key outcomes of interest.We used the Mantel-Haenszel,Rothman-Boice method for fixed effects and DerSimonian-Laird method for random-effects.For subgroup analyses,we separated the studies by type of IBD and type of herbal medicine to determine confounding factors and reliability.RESULTS:Seven placebo controlled clinical trials met our criteria and were included(474 patients).Comparison of herbal medicine with placebo yielded a significant RR of 2.07(95%CI:1.41-3.03,P=0.0002)for clinical remission;a significant RR of 2.59(95%CI:1.24-5.42,P=0.01)for clinical response;a non-significant RR of 1.33(95%CI:0.93-1.9,P=0.12)for endoscopic remission;a non-significant RR of 1.69(95%CI:0.69-5.04)for endoscopic response;a non-significant RR of 0.64(95%CI:0.25-1.81)for histological remission;a non-significant RR of 0.86(95%CI:0.55-1.55)for histological response;a non-significant RR of 0.95(95%CI:0.52-1.73)for relapse;a non-significant RR of 0.89(95%CI:0.75-1.06,P=0.2)for any adverse events;and a non-significant RR of 0.97(95%CI:0.37-2.56,P=0.96)for serious adverse events.CONCLUSION:The results showed that herbal medicines may safely induce clinical response and remission in patients with IBD without significant effects on endoscopic and histological outcomes,but the number of studies is limited to make a strong conclusion. | Roja Rahimi Shekoufeh Nikfar Mohammad Abdollahi | 2013 | World Journal of Gastroenterology2013，19，34： | 4 |
| 7 | New biologic therapeutics for ulcerative colitis and Crohn’s disease显示文摘 | Shilan Mozaffari Shekoufeh Nikfar Amir Hossein Abdolghaffari Mohammad Abdollahi | 2014 | Expert Opinion on Biological Therapy2014，，5： | 3 |
| 8 | A systematic review of the safety of probiotics显示文摘 | Tina Didari Sara Solki Shilan Mozaffari Shekoufeh Nikfar Mohammad Abdollahi | 2014 | Expert Opinion on Drug Safety2014，，2： | 3 |
| 9 | A Meta-Analysis and Systematic Review on the Effect of Probiotics in Acute Diarrhea显示文摘 | Pooneh Salari Shekoufeh Nikfar Mohammad Abdollahi | 2012 | InflammationandAllergy-Drug Targets (Formerly Current Drug Targets - InflammationandAllergy)2012，，1： | 3 |
| 10 | Effect of Satureja khuzestanica essential oil on male rat fertility显示文摘 | Sulmaz Haeri Bagher Minaie Gholamreza Amin Shekoufeh Nikfar Reza Khorasani Hadi Esmaily Alinazar Salehnia Mohammad Abdollahi | 2006 | Fitoterapia2006，，7： | 2 |
| 11 | Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: A meta-analysis显示文摘 | Roja Rahimi Shekoufeh Nikfar Ali Rezaie Mohammad Abdollahi | 2007 | Reproductive Toxicology2007，，2： | 2 |
| 12 | Systematic Review and Meta-Analysis of the Efficacy and Tolerability of Nicotine Preparations in Active Ulcerative Colitis显示文摘 | Shekoufeh Nikfar Solmaz Ehteshami-Ashar Roja Rahimi Mohammad Abdollahi | 2010 | Clinical Therapeutics2010，，14： | 2 |
| 13 | A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease显示文摘 | Ehteshami-Afshar S Nikfar S Rezaie A | 2011 | Arch Med Sci2011，7，6： | 1 |
| 14 | Monitoring of national drug policy and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran显示文摘 | Shekoufeh Nikfar Abbas Kebriaeezadeh Reza Majdzadeh | 2005 | BMC lnt Health Hum Rights2005，5，5： | 1 |
| 15 | The efficacy and tolerability of ex- enatide in comparison to placebo ; a systematic review and meta-analy- sis of randomized clinical trials显示文摘 | Nikfar S Abdollabi M Salari P | 2012 | J Pharm Pharm Sci2012，15，1： | 1 |
| 16 | Effects of Satureja khuzestanica on Serum Glucose, Lipids and Markers of Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Double-Blind Randomized Controlled Trial显示文摘 | Sanaz Vosough-Ghanbari Roja Rahimi Shabnam Kharabaf Shima Zeinali Azadeh Mohammadirad Somayeh Amini Nargues Yasa Alinazar Salehnia Tayebeh Toliat Shekoufeh Nikfar Bagher Larijani Mohammad Abdollahi | 2008 | Evidence-Based Complementary and Alternative Medicine2008，，4： | 1 |
| 17 | A review on the role ofantioxidants in the management of diabetes and its complications显示文摘 | Rahimi R Nikfar S Larijani B | 2005 | Biomed Pharmacother2005，59，7： | 1 |
| 18 | Biochemical and Histopathological Evidences for Beneficial Effects of Satureja Khuzestanica Jamzad Essential Oil on the Mouse Model of Inflammatory Bowel Diseases显示文摘 | Ghazal Ghazanfari Bagher Minaie Narges Yasa Leila Ashtaral Nakhai Azadeh Mohammadirad Shekoufeh Nikfar Gholamreza Dehghan Vahid Shetab Boushehri Hamidreza Jamshidi Reza Khorasani Alinazar Salehnia Mohammad Abdollahi | 2006 | Toxicology Mechanisms and Methods2006，，7： | 1 |
| 19 | A meta-analysis of the role of st- atins on renal outcomes in patients with chronic kidney disease: Is the duration of therapy important? 显示文摘 | Nikotic D Banach M Nikfar S | 2013 | lnt J Cardiol2013，168，6： | 1 |
| 20 | The Efficacy and Tolerability of Exenatide in Comparison to Placebo;A Systematic Review and Meta-Analysis of Randomized Clinical Trials显示文摘 | Nikfar S Abdollahi M Salari P | 2012 | J Pharm Pharmaceut Sci2012，15，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员